A sensitive AAV transduction inhibition assay assists evaluation of critical factors for detection and concordance of pre-existing antibodies

Pre-existing antibodies to viral capsids may have a negative impact on the efficacy and safety of adeno-associated virus (AAV)-based gene therapies. Total antibody (TAb) and/or cell-based transduction inhibition (TI) assays have been used to exclude seropositive individuals in clinical studies. Publ...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yonghua, Rohde, Michelle, Zeitler, Jennifer, Namburi, Sai Valli Srujana, Cao, Liching, Hu, Jing, Meyer, Kathleen, Lu, Yanmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618111/
https://www.ncbi.nlm.nih.gov/pubmed/37920239
http://dx.doi.org/10.1016/j.omtm.2023.101126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618111/
https://www.ncbi.nlm.nih.gov/pubmed/37920239
http://dx.doi.org/10.1016/j.omtm.2023.101126

Ejemplares similares